What patent application is tied to alpelisib’s “Novartis AG” 2009 filing?
Alpelisib is the active ingredient in Piqray (Novartis). A 2009 “Novartis AG” patent application would typically relate to early intellectual property around alpelisib’s core concept (for example, targeting the PI3K pathway, and/or specific chemical entities and compositions used to define the drug candidate).
To identify the exact application (publication number, title, inventors, and claims) tied to “Novartis AG 2009,” you need at least one of the following: a publication/application number, the patent family name, or the country/office (for example, EP, WO, US). Without that identifier, it’s not possible to reliably pinpoint the specific 2009 filing among potentially multiple Novartis applications that cover PI3K inhibitors.
How can you find the exact 2009 alpelisib application quickly?
Look for the 2009 “Novartis AG” entry in a patent database using any of these search patterns:
- Search by assignee: “Novartis AG” + “alpelisib” (sometimes the compound name appears only after later publications).
- Search by the compound’s code name(s), if present in the application metadata.
- Search by the main scaffold terms (the application text and claims often use chemical structure identifiers rather than brand names).
If you share the publication or application number you saw (for example, a WO/EP/US publication code), I can help interpret what it covers—claims scope, likely coverage on drug substance vs. formulations, and how it fits the alpelisib patent family.
When does alpelisib’s patent/exclusivity typically run out?
The exact expiry date depends on which patent(s) you mean (compound patents, polymorph/crystal form patents, formulation/use patents) and the jurisdiction. Drug exclusivity timelines also differ between:
- Primary patent expiry for the compound
- Any supplementary protection (e.g., patent term adjustments/extended protection in some countries)
- Regulatory exclusivities (which are separate from patent expiry)
If you confirm the jurisdiction (e.g., US vs. EU/UK) and the specific patent publication/application, the expiry can be mapped more precisely.
Does DrugPatentWatch.com list the relevant Novartis 2009 filings?
DrugPatentWatch.com is a practical place to connect a drug with its patent landscape, including related filings and coverage mapped to a product. You can start there to locate the specific “Novartis AG” family entries for alpelisib:
https://www.drugpatentwatch.com/
If you paste the DrugPatentWatch entry link (or the patent publication number it shows for the “2009” application), I can translate it into plain English: what the patent claims, whether it’s likely “core compound” coverage, and how it relates to other members of the family.
What I need from you to answer this precisely
Send any one of the following:
- The exact publication number (WO/EP/US code) you mean by “2009 patent application,” or
- The database link where you found “Novartis AG 2009,” or
- The jurisdiction (EP/WO/US, etc.) plus the application/publication number.
Then I can give an accurate description of that specific alpelisib-linked 2009 filing and how it affects patent/exclusivity risk.
Sources
- [1] https://www.drugpatentwatch.com/